Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3047964 | 0.80 | NAAA (0.39) | ALDH1A1HPGDMAPTSMN1; SMN2POLB | |
| SCHEMBL3049506 | 0.79 | SOS1 (0.39) | ALDH1A1HPGDMAPTSMN1; SMN2POLB | |
| SCHEMBL13340721 | 0.76 | NAAA (0.49) | ALDH1A1HPGDSMN1; SMN2LMNAHTT | |
| SCHEMBL17524653 | 0.74 | NAAA (0.57) | ALDH1A1HPGDSMN1; SMN2POLBLMNA | |
| SCHEMBL9557086 | 0.74 | NAAA (0.57) | ALDH1A1HPGDSMN1; SMN2POLBLMNA | |
| SCHEMBL19281759 | 0.74 | NAAA (0.57) | ALDH1A1HPGDSMN1; SMN2POLBLMNA | |
| SCHEMBL19810282 | 0.73 | NAAA (0.57) | ALDH1A1HPGDSMN1; SMN2LMNAHTT | |
| SCHEMBL18007116 | 0.73 | NAAA (0.57) | ALDH1A1HPGDSMN1; SMN2LMNAHTT | |
| SCHEMBL31036156 | 0.72 | HPGD (0.69) | ALDH1A1HPGDMAPTSMN1; SMN2POLB | |
| SCHEMBL3052924 | 0.72 | HPGD (0.69) | ALDH1A1HPGDMAPTSMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7767645-B2 | SH2 domain binding inhibitors | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-08-03 | — | — | US | disclosed |
| US-20080132469-A1 | 2-{(9S,10S,14R,18S)-7,16,19-Triaza-18-(carbamoylmethyl)-14-[(5-methyl indolyl)methyl]-8,17,20-trioxo-10-[4-(phosphonomethyl)phenyl]spiro[5.14]icos-11-en-9-yl}acetic acid; anticarcinogen | GOVERNMENT OF THE UNITED STATES, REPRESENTED BY THE SECRETARY, DEPARTMENT (US) | 2008-06-05 | — | — | US | disclosed |
| US-20050119163-A1 | SH2 domain binding inhibitors | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, (US) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132469-A1 | 2-{(9S,10S,14R,18S)-7,16,19-Triaza-18-(carbamoylmethyl)-14-[(5-methyl indolyl)methyl]-8,17,20-trioxo-10-[4-(phosphonomethyl)phenyl]spiro[5.14]icos-11-en-9-yl}acetic acid; anticarcinogen | ICOSLG, ICOS, LCK | ALDH1A1 1958/4885HPGD 4176/4885MAPT 4066/4885 |
| US-20050119163-A1 | SH2 domain binding inhibitors | GRB2, SRC, LCK | ALDH1A1 3924/4885HPGD 4623/4885MAPT 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.